tiprankstipranks
ELYM to Explore Strategic Alternatives
Market News

ELYM to Explore Strategic Alternatives

Eliem Therapeutics (NASDAQ: ELYM), a biotech company gained in pre-market trading at the time of publishing on Thursday after the company announced that it has completed a strategic review of its business and will halt the development of its Kv7 program.

Don't Miss our Black Friday Offers:

The company has engaged Leerink Partners as a strategic advisor and will conduct a comprehensive exploration of its strategic alternatives. Eliem stated in its press release that its strategic alternatives “may include, but are not limited to, an acquisition, merger, business combination, or other transaction. There can be no assurance that its exploration will result in Eliem pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.”

ELYM stock has tanked by more than 15% year-to-date.

Related Articles
TheFlyEliem Therapeutics to change corporate name to Climb Bio
TipRanks Auto-Generated NewsdeskEliem Therapeutics: Executive Changes Amid Strategic Shift
TipRanks Auto-Generated NewsdeskEliem Therapeutics Names Brett Kaplan as New COO
Go Ad-Free with Our App